Dernières nouvelles pour Canopy Gwth (NASDAQ:CGC) Stock

Canopy Gwth

Canopy Growth

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth merged its US assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.

Canopy Growth Corporation - Common Shares

Canopy Growth Corp

Capital Group Fixed Income ETF Trust Capital Group Core Bond ETF

CENTRAL GLASS CO LTD ORD by Central Glass Co., Ltd.

Central Glass Co Ltd

COMMERCE GROUP CORP by Commerce Group Corp.

Commerce Group Corp

Capital Group Core Plus Income ETF Capital Group Core Plus Income ETF

Capital Group Conservative Equity ETF Capital Group Conservative Equity ETF

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GEATF">Radiko Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GEATF#OTC">GEATF</a>) shares closed up 900.00% at $1e-05</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 26.55% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 25.00% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 12.36% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 10.39% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 8.14% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 7.76% at $4.31</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed up 7.51% at $0.55</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 7.35% at $1.49</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 7.31% at $0.18</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 6.98% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed up 6.23% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/CRON">Cronos Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) shares closed up 4.54% at $2.24</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 4.39% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed up 4.06% at $0.91</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 3.62% at $4.58</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 3.48% at $0.28</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 3.02% at $0.05</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 37.78% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 18.67% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 18.18% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 15.67% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 13.88% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 9.71% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 8.57% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 7.01% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed down 6.81% at $0.13</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 5.64% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 5.22% at $2.30</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 5.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GENE">Genetic Technologies</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) shares closed down 4.00% at $0.74</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BBRRF

CARA

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CLSH

CNBX

CNPOF

CNTMF

CRON

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

CWBHF

EAST

FFNTF

FUAPF

GBHPF

GEATF

GENE

GNLN

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

LVRLF

OILFF

RMHB

SOLCF

TGIFF

UGRO

XXII

Marijuana Stock Movers For October 3, 2024

The cannabis sector has captivated investors, promising a green rush of potential profits. However, the path to profitability has been rocky, marked by regulatory hurdles, intense competition, and, at times, a volatile market. Many investors are left wondering: Is the cannabis sector still a viable long-term investment, or is the green rush fading? While not simple, the answer increasingly indicates a positive outlook driven by evolving regulations and strong market fundamentals.
<h2>A Budding Legal Landscape</h2>
The cannabis industry is undergoing a significant transformation that is being driven by a changing regulatory environment. The acceptance of medical and recreational cannabis is increasing across many jurisdictions. This trend is particularly evident in the United States, where a growing number of states have legalized recreational cannabis, creating an expanding market.
While federal legalization in the U.S. remains a hurdle, the potential for it is undeniable. Should it occur, federal legalization would likely trigger a significant surge in industry growth and investment, leading to market stability and a more favorable business environment. This evolving regulatory landscape represents a key driver for the cannabis sector, making it an increasingly attractive investment opportunity for those with a long-term perspective.
<h2>Fueling the Green Rush: Market Drivers</h2>
The cannabis sector&#39;s growth is driven by multiple factors that make it increasingly attractive for investors. Consumer demand is surging, fueled by shifting perceptions of cannabis and the increasing availability of diverse products catering to a wide range of consumer preferences.
Moreover, the medical cannabis segment is experiencing rapid growth, driven by advancements in research and the development of new cannabis-based therapies. Medical cannabis is being explored for its potential to treat a wide range of conditions, creating new opportunities for companies focused on this sector.
Finally, the cannabis market is expanding beyond established jurisdictions like Canada and the United States. As more countries legalize cannabis, the global market is poised to reach new heights, offering significant growth opportunities for cannabis companies with international reach.
<h2>Leading Cannabis Companies Show Signs of Progress&nbsp;</h2>
The surge in consumer demand, fueled by changing perceptions and diverse product offerings, attracts significant investment in the cannabis sector. This is evident in the performance of leading companies, many demonstrating a shift towards profitability and a more focused approach to growth.
For example, Aurora Cannabis (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acb#NASDAQ">ACB</a>) recently achieved a significant milestone by reporting positive free cash flow for the first time. Aurora&#39;s earnings report for the first quarter of fiscal 2025 revealed a positive free cash flow of $6.5 million, reflecting a strategic focus on cost management and operational efficiency.
This shift is further exemplified by Aurora&#39;s strategic move towards the higher-margin medical cannabis segment, leveraging its expertise and resources to capitalize on the growing demand for medical cannabis products. In Q1 2025, Aurora reported record revenue in its global medical cannabis segment, indicating a successful shift towards this lucrative niche.
While Aurora has made significant progress, it still faces challenges, such as ongoing competition and the need for continued fiscal discipline. However, the company&#39;s recent achievements signal a positive trajectory for its future, especially considering its debt-free status, which allows for more financial flexibility.
Canopy Growth (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) has taken a different path, prioritizing profitability and cost control over rapid growth. This strategic shift has significantly improved the company&#39;s Adjusted EBITDA, demonstrating its commitment to generating sustainable profits. In Q1 2025, Canopy&#39;s Adjusted EBITDA loss narrowed by over 75% compared to the previous year, highlighting the company&#39;s success in cost control and operational efficiency.&nbsp;
This success is also reflected in the company&#39;s recent debt reduction efforts, securing a favorable amendment to its term loan agreement, further enhancing its financial flexibility. The company&#39;s focus on expanding into key markets like Germany, where it is augmenting its Canadian-sourced flower with EU-based supply to meet growing demand, showcases its ambition to capture a larger share of the global medical cannabis market.
Canopy Growth, like Aurora, still needs to address its ongoing losses. Despite recent improvements, the company remains unprofitable, which is a concern for investors seeking a consistent return on their investment. Additionally, the cannabis industry is prone to volatility, and Canopy&#39;s stock price has been highly volatile in recent years, requiring investors to have a strong risk tolerance.
<h2>Beyond the Individual Stock: The Power of Cannabis ETFs</h2>
For investors seeking diversified exposure to the cannabis sector without choosing individual stocks, Cannabis ETFs offer a convenient option. The AdvisorShares Pure U.S. Cannabis ETF (ARCA:MSOS) is a good starting point, offering investors a basket of publicly traded U.S. cannabis companies.
While ETFs can provide diversification and access to a broader market, it&#39;s important to remember that they are not without risks. ETFs are subject to market volatility, and the performance of the underlying companies within the ETF can impact their performance.
<h2>The Green Rush Continues</h2>
While the path has not been easy, the cannabis sector continues to demonstrate significant potential for long-term growth. The changing regulatory environment is creating a more favorable landscape for cannabis companies, while solid market fundamentals are driving consumer demand and fueling industry expansion.&nbsp;
The ongoing developments in medical cannabis research are further bolstering the sector&#39;s potential, while the emergence of new markets and the growing popularity of diverse cannabis products are contributing to the industry&#39;s growth trajectory.
Investors who conduct thorough research, manage risk effectively, and maintain a long-term perspective can position themselves to capitalize on the potential rewards of this evolving and dynamic sector. The green rush may be ongoing, but navigating its complexities requires careful planning and a thoughtful investment strategy.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/profit-from-the-green-wave-top-cannabis-stocks-to-watch/">Profit from the Green Wave: Top Cannabis Stocks to Watch</a>&quot; first appeared on MarketBeat.

Earnings

Government

News

Penny Stocks

Regulations

Sector ETFs

Offerings

Small Cap

Trading Ideas

ETFs

MSOS

Profit from the Green Wave: Top Cannabis Stocks to Watch

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CWWBF">Plant Based Investment</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWWBF#OTC">CWWBF</a>) shares closed up 9900.00% at $0.0001</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 38.10% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 12.40% at $2.38</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 10.71% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 9.30% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed up 8.73% at $13.20</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 7.11% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 3.84% at $0.01</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/AUSAF">Australis Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUSAF#OTC">AUSAF</a>) shares closed down 99.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 16.41% at $0.18</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 10.40% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 8.30% at $4.41</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed down 7.96% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 6.68% at $19.23</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 5.80% at $1.33</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 4.28% at $0.45</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 3.98% at $1.68</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 3.76% at $2.05</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed down 3.70% at $2.57</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 3.57% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 3.39% at $1.99</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AUSAF

CBDY

CRBP

CANNIBIS GROWTH OPTY CORP by Cannabis Growth Opportunity Corp.

CWWBF

CXXIF

ELLXF

GRWG

SNDL

TLRY

YCBD

Cannabis Stock Gainers And Losers From October 1, 2024

Legal

AKAN

IMCC

LFLY

MAPS

Lawmakers Urge DEA To Finalize Marijuana Rescheduling Proposal

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 22.31% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 19.33% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 12.97% at $2.70</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 6.06% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 5.04% at $4.82</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 4.26% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed up 4.17% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed up 3.90% at $11.19</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed up 3.72% at $0.93</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 3.31% at $2.50</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/AUSAF">Australis Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUSAF#OTC">AUSAF</a>) shares closed down 99.01% at $0.0001</li>
<li><a href="https://www.benzinga.com/quote/CHOOF">Choom Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CHOOF#OTC">CHOOF</a>) shares closed down 90.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/GRNH">GreenGro Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GRNH#OTC">GRNH</a>) shares closed down 90.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 14.92% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 13.69% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 12.28% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 9.09% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 7.11% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 6.98% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Props</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 6.89% at $0.54</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 5.76% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 3.70% at $0.01</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLGVF

CHOOF

CPHRF

GRNH

NWVCF

ZDPY

Bearish Monday For Marijuana Stocks - Australis Capital, Choom Holdings Among Top Gainers

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) stock is trading higher on Monday, along with other shares in the cannabis sector, following a report suggesting that Vice President Kamala Harris wants to <a href="https://www.benzinga.com/markets/cannabis/24/09/41009554/tilray-brands-launches-hemp-derived-delta-9-thc-drinks-in-key-u-s-markets">legalize marijuana</a>.
What To Know: Harris said in an <a href="https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-as-democratic-presidential-nominee/">interview</a> on the All the Smoke podcast that, &#8220;I just think we have come to a point where we have to understand that we need to legalize it and stop criminalizing this behavior.&#8221;
Harris also stated that, &#8220;I just feel strongly, people should not be going to jail for smoking weed. And we know historically what that has meant and who has gone to jail."
The episode of the podcast was released Monday. Its hosts are former NBA players Matt Barnes and Stephen Jackson. Other stocks in the cannabis sector that are moving higher following Harris&#8217;s comments, include Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) and Canopy Growth Corporation (NASADQ:CGC)
How To Buy Tilray Brands Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/markets/cannabis/24/09/41096880/gop-senator-leads-bipartisan-effort-to-seal-low-level-marijuana-possession-records-providing-sec">GOP Senator Leads Bipartisan Effort To Seal Low-Level Marijuana Possession Records, Providing &#8216;Second Chance&#8217;</a>
TLRY Price Action: At the time of writing, Tilray shares are trading 2.59% higher at $1.78, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo by noexcusesradio via Pixabay

What's Going On With Tilray Brands Stock Monday?

WIIM

Shares of cannabis stocks are trading higher following a report suggesting that Vice President Harris wants to legalize marijuana.

<a href="https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-as-democratic-presidential-nominee/">https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-as-democratic-presidential-nominee/</a>
Vice President Kamala Harris says it's time to legalize marijuana—marking the first time she has publicly discussed her position on cannabis since becoming the Democratic presidential nominee.
"I just feel strongly, people should not be going to jail for smoking weed," she said in an interview with the All the Smoke podcast that was released on Monday. "And we know historically what that has meant and who has gone to jail."
"Second, I just think we have come to a point where we have to understand that we need to legalize it and stop criminalizing this behavior," Harris told hosts Matt Barnes and Stephen Jackson, who are former NBA players.
"Actually this is not a new position for me," Harris, who sponsored a federal cannabis legalization bill as a U.S. senator, said. "I have felt for a long time we need to legalize it. So that's where I am on that."
Until now, Harris had not made her position on marijuana part of her current campaign for the White House.
Earlier this month, <a href="https://www.marijuanamoment.net/marijuana-legalization-is-an-issue-for-the-states-vp-candidate-tim-walz-says-adding-that-electing-democrats-to-congress-will-boost-cannabis-reform/">Democratic vice presidential nominee Tim Walz said he thinks marijuana legalization is an issue that should be left to individual states</a>, adding that electing more Democrats to Congress could also make it easier to pass federal reforms like cannabis banking protections.
"I think it's an issue for the states on some of those, and that's the way the states have done it," Walz, who is Minnesota's governor and previously served in Congress, said, dodging a reporter's direct question about national cannabis legalization.
During that interview, Walz highlighted two incremental reform issues: medical marijuana access for veterans who receive healthcare through the Department of Veterans Affairs (VA) as well as passage of federal legislation that would ease restrictions for banks that due business with marijuana companies.
If Democrats take control of both houses of Congress, he said, those matters might be easier to address.
"There's work to be done nationally around the banking issue," he said in the Spectrum News&nbsp;interview&nbsp;that was posted on September 14, "and I think that's something that if we get a working Congress who actually wants to solve some issues—when we have the Democrats in charge of the House and the Senate—then we can start to see if some of those things make sense."
Harris, for her part, has spoken in favor of federal legalization in the past, for example at&nbsp;<a href="https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-since-joining-biden-ticket-signaling-potential-shift-ahead-of-election/">a closed-door roundtable event with cannabis pardon recipients</a> in March. In her previous run for president, Harris also&nbsp;<a href="https://www.marijuanamoment.net/harris-backed-broad-drug-decriminalization-during-2020-election-run-resurfaced-aclu-questionnaire-shows/">backed full federal decriminalization for simple drug possession</a>.
Meanwhile former President Donald Trump said recently during his campaign for a second term that he now supports federal marijuana rescheduling and marijuana banking access.
"As President, we will continue to focus on research to unlock the medical uses of marijuana to a Schedule 3 drug, and work with Congress to pass common sense laws, including safe banking for state authorized companies, and supporting states rights to pass marijuana laws, like in Florida, that work so well for their citizens," Trump posted to social media earlier this month.
<a href="https://www.marijuanamoment.net/trump-says-florida-marijuana-legalization-ballot-measure-will-be-very-good-for-the-state-adding-that-medical-use-is-absolutely-amazing-for-patients/">Trump also recently discussed the medical benefits</a>&nbsp;of cannabis and said legalization would be "very good" for Florida, which will consider the reform at the ballot box in November's election.
The Harris–Walz campaign, however, has&nbsp;<a href="https://www.marijuanamoment.net/harris-campaign-accuses-trump-of-lying-about-marijuana-reform-support-but-again-declines-to-detail-her-own-platform/">accused Trump of lying about his support for marijuana reform</a>—arguing that his "blatant pandering" runs counter to his administration's record on cannabis.
Following Trump's recent announcement of support for the Florida cannabis legalization ballot measure, the Democratic campaign has been working to remind voters that while in office, <a href="https://www.marijuanamoment.net/harris-accuses-trump-of-brazen-flip-flops-on-marijuana-as-former-president-endorses-florida-legalization-measure/">Trump "took marijuana reform backwards."</a>
In a memo from a senior campaign spokesperson, the Harris-Walz campaign accused Trump of "brazen flip flops" on cannabis, saying it's one of the Republican former president's "several bewildering ‘policy proposals' that deserve real scrutiny."
The posturing by the presidential candidates comes amid an ongoing process of moving marijuana to the less-restrictive Schedule III of the Controlled Substances Act (CSA).
The Department of Health and Humans Services (HHS) this spring recommended moving the drug to Schedule III, but the action has faced resistance from the Drug Enforcement Administration (DEA), which has&nbsp;<a href="https://www.marijuanamoment.net/dea-schedules-hearing-on-marijuana-rescheduling-proposal-delaying-final-rule/">scheduled a hearing on the proposal for December 2</a>—after the presidential election,&nbsp;<a href="https://www.marijuanamoment.net/dea-pushing-marijuana-rescheduling-past-election-is-incredibly-disappointing-congressman-says-as-stakeholders-react-to-hearing/">raising concerns that the process will not be completed</a>&nbsp;until after a new president is inaugurated.
Meanwhile, Trump also recently&nbsp;<a href="https://www.marijuanamoment.net/trump-claims-harris-jailed-thousands-and-thousands-of-black-people-over-marijuana-but-her-actual-record-as-a-prosecutor-is-more-nuanced/">went after Harris over her prosecutorial record on marijuana</a>, claiming that she put "thousands and thousands of Black people in jail" for cannabis offenses—but the full record of her time in office is more nuanced.
Trump's line of attack, while misleading, was nonetheless notable in the sense that the GOP presidential nominee implied that he disagrees with criminalizing people over marijuana and is moving to leverage the idea that Harris played a role in racially disproportionate mass incarceration.
As president, Trump largely stayed true to his position that marijuana laws should be handled at the state-level, with no major crackdown on cannabis programs as some feared after then-Attorney General Jeff Sessions rescinded the Obama era federal enforcement guidance. In fact, Trump&nbsp;<a href="https://www.marijuanamoment.net/gop-senator-reveals-what-trump-said-about-jeff-sessionss-anti-marijuana-moves/">criticized the top DOJ official and suggested the move should be reversed</a>.
While he was largely silent on the issue of legalization, he did tentatively endorse a bipartisan bill to&nbsp;<a href="https://www.marijuanamoment.net/trump-says-he-supports-senate-marijuana-legislation/">codify federal policy respecting states' rights to legalize</a>.
That said, on several occasions he released signing statements on spending legislation stipulating that he&nbsp;<a href="https://www.marijuanamoment.net/trump-issues-signing-statement-on-medical-marijuana-provision-of-funding-bill/">reserved the right to ignore a long-standing rider</a>&nbsp;that prohibits the Justice Department from&nbsp;<a href="https://www.marijuanamoment.net/trump-says-he-can-ignore-medical-marijuana-protections-passed-by-congress/">using its funds to interfere with state-legal medical marijuana programs</a>.
Before President Joe Biden bowed out of the race, his campaign made much of the president's mass cannabis pardons and rescheduling push,&nbsp;<a href="https://www.marijuanamoment.net/biden-smokes-trump-on-marijuana-policy-campaign-says-after-presidents-rescheduling-announcement/">drawing a contrast with the Trump administration's record</a>. The Harris campaign so far has not spoken to that particular issue, and the nominee has yet to publicly discuss marijuana policy issues since her own campaign launched.

Macro Economic Events

Politics

Econ #s

Economics

General

"Kamala Harris Says 'We Need To Legalize' Marijuana For First Time As Democratic Presidential Nominee" - Marijuana Moment

<a href="https://cannabiswire.com/news/2024/09/26/for-the-first-time-national-agriculture-regulators-group-grapples-with-cannabinoid-hemp/">https://cannabiswire.com/news/2024/09/26/for-the-first-time-national-agriculture-regulators-group-grapples-with-cannabinoid-hemp/</a>
&nbsp;

"National Agriculture Regulators Group Grapples With Intoxicating Hemp For The First Time; FDA's Norm Birenbaum Says Existing FDA Regulatory Frameworks 'Do Not Apply To Large Segments Of The Market, Like Inhalable Products, Where We Have Tremendous Concerns'" - Cannabis Wire

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CHOOF">Choom Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CHOOF#OTC">CHOOF</a>) shares closed up 900.00% at $1e-05</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 100.00% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 20.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 19.16% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 17.31% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 16.41% at $21.35</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 12.21% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 11.11% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 9.30% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed up 5.07% at $0.49</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 3.17% at $1.24</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 3.08% at $0.05</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 16.43% at $2.70</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed down 11.38% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 11.11% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 9.40% at $0.23</li>
<li><a href="https://www.benzinga.com/quote/GENE">Genetic Technologies</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) shares closed down 6.56% at $0.76</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 3.91% at $4.41</li>
<li><a href="https://www.benzinga.com/quote/OGI">OrganiGram Holdings</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed down 3.83% at $1.74</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 3.73% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed down 3.58% at $13.20</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 3.08% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 3.05% at $0.48</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMMJ

Cannabis Stock Movers For September 25, 2024

<a href="https://www.marijuanamoment.net/dea-calls-for-massive-increases-in-psilocybin-ibogaine-and-thc-manufacturing-this-year-to-meet-research-demands/">https://www.marijuanamoment.net/dea-calls-for-massive-increases-in-psilocybin-ibogaine-and-thc-manufacturing-this-year-to-meet-research-demands/</a>
The Drug Enforcement Administration (DEA) is proposing a dramatic increase in its 2023 production quotas for marijuana compounds and psychedelics like psilocybin and ibogaine to "support research and clinical trials" into the substances.
DEA wants to nearly double the amount of psilocybin, psilocyn and delta-9 THC that's manufactured compared to initial levels set for this year, while quintupling how much ibogaine is produced. It also wants 23 times as much of "other tetrahydrocannabinol," raising the quota from 15,000 grams to 350,000 grams for 2023.
The agency had already increased its initial quota for various controlled substances, including cannabis and psychedelics, late last year when it finalized the numbers. But now, in a notice published in the Federal Register on Tuesday, DEA said that more significant changes are warranted.
For psilocybin, the proposed new quota is 15,000 grams, rather than 8,000 grams as previously set for 2023. DEA also wants 24,000 grams of the psychedelic compound psilocyn, double its prior 12,000-gram quota.
The now-increased initial 2023 levels for both of the "magic mushroom" components already represented significant increases from those set for prior years, demonstrating the ongoing heightened level of interest in researching psychedelics over time.
DEA is also proposing to manufacture 150 grams of ibogaine—five times the amount it called for in December 2022.
While the agency didn't change its 6.7 million-gram quota for marijuana for the year, it is now calling for the manufacturing of 628,460 grams of delta-9 THC, rather than 384,460 grams—a 63 percent increase.
For all other tetrahydrocannabinol, DEA wants 350,000 grams, a notable increase from its prior 15,000-gram quota—a massive 2,233 percent increase.
The proposed increases, which are subject to a 30-day public comment period starting on Tuesday, comes in the context of an ongoing administrative review into the scheduling status of cannabis that DEA is actively carrying after receiving a recommendation from the U.S. Department of Health and Human Services (HHS) to <a href="https://www.marijuanamoment.net/top-federal-health-agency-releases-highly-redacted-marijuana-scheduling-recommendation-letter-to-dea/">move marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA)</a>.
It also comes as experts await a <a href="https://www.marijuanamoment.net/after-latest-clinical-trial-mdma-therapy-for-ptsd-is-on-track-for-fda-consideration-next-year/">potential federal approval for certain psychedelics like psilocybin and MDMA</a> as therapeutics for the treatment of serious mental health conditions.
The updated quotas reflect "the estimated medical, scientific, research, and industrial needs of the U.S., for lawful export requirements, and for the establishment and maintenance of reserve stocks," DEA <a href="https://www.federalregister.gov/public-inspection/2023-23931/proposed-adjustments-to-the-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances">said</a> in its new quota increase notice.
"DEA is proposing increases to the [aggregate production quotas] for the following schedule I substances: all other tetrahydrocannabinol, delta-9-tetrahydrocannabinol, ibogaine, psilocybin, and psilocyn," it said. "These proposed increases are to support research and clinical trials by DEA-registered schedule I researchers. These proposed increases demonstrate DEA's support for research with schedule I controlled substances."
 DEA's prior "final" quotas that were published late last year already <a href="https://www.marijuanamoment.net/dea-proposes-dramatic-increases-in-marijuana-and-psychedelics-production-in-2023-for-research/">contained increases compared to its initial proposal</a>, with <a href="https://www.marijuanamoment.net/dea-proposes-even-higher-2023-production-quotas-for-psychedelics-like-mdma-and-psilocyn/">the agency calling for the manufacturing of more psychedelic compounds</a> such as MDMA, psilocyn and 5-MeO-DMT.
This year's 6.7 million-gram quota for marijuana is more than double DEA's final <a href="https://www.marijuanamoment.net/dea-again-boosts-2022-production-goals-for-psychedelics-like-psilocybin-mdma-and-dmt/">cannabis quota for 2022, which was 3.2 million grams.</a>&nbsp;<a href="https://www.marijuanamoment.net/dea-boosts-psilocybin-mdma-and-dmt-production-levels-again-in-final-quotas-for-2021/">It was 2 million grams for 2021</a>.
Growing millions of grams of cannabis may be easier since&nbsp;<a href="https://www.marijuanamoment.net/dea-finally-breaks-federal-marijuana-grower-monopoly-with-two-new-companies-harvesting-cannabis-approved-by-agency/">DEA finally authorized additional manufacturers</a>&nbsp;at the beginning of the year. Those approved cultivators are now able to apply for&nbsp;<a href="https://www.marijuanamoment.net/top-federal-drug-agency-seeking-marijuana-grower-able-to-cultivate-and-analyze-4-million-grams-of-cannabis/">a contract to be federal marijuana suppliers</a>&nbsp;for study purposes under the National Institute on Drug Abuse (NIDA).
The agency has touted its Schedule I drug production quotas as evidence that is supports rigorous research into the substances, but it's faced criticism from advocates and scientists over actions that are viewed as antithetical to promoting studies.
Following pushback, DEA recently retreated on&nbsp;<a href="https://www.marijuanamoment.net/dea-abandons-proposal-to-ban-two-more-psychedelics-after-being-challenged-by-scientists/">a proposed ban on psychedelic compounds</a>&nbsp;that scientists say have research value.
That marked another win for scientific community, coming just one month after DEA&nbsp;<a href="https://www.marijuanamoment.net/dea-cancels-proposed-ban-of-five-psychedelics-giving-scientists-more-time-to-research-therapeutic-benefits/">abandoned separate plans to place five tryptamine psychedelics in Schedule I</a>.
Meanwhile, a federal appeals court recently ruled against DEA in a <a href="https://www.marijuanamoment.net/federal-appeals-court-rules-against-dea-in-psilocybin-rescheduling-lawsuit-brought-by-doctor-who-wants-to-give-psychedelic-to-cancer-patients/">lawsuit over a Washington State doctor's petition to reschedule psilocybin</a>. The court said DEA failed to explain its reasoning when it denied the petition, and it ordered the agency to provide a more complete justification.
With respect to the agency's marijuana scheduling review, a coalition of 31 bipartisan House lawmakers has sent a letter to DEA Administrator Anne Milgram, urging her to <a href="https://www.marijuanamoment.net/31-bipartisan-house-lawmakers-push-dea-to-consider-merits-of-marijuana-legalization-as-it-completes-scheduling-review/">take into account congressional and state marijuana legalization efforts</a> as it completes that assessment. They also criticized the limitations of simple rescheduling as they push for complete a complete removal of marijuana from the CSA.
The letter serves as a counterbalance to other recent messages DEA has received from congressional opponents of reform and former DEA and White House drug czars who&nbsp;<a href="https://www.marijuanamoment.net/marijuana-rescheduling-would-supersize-the-industry-former-dea-heads-and-white-house-drug-czars-warn-biden-administration/">argue that even moving marijuana to Schedule III would go too far</a>.
A coalition of 14 Republican congressional lawmakers recently&nbsp;<a href="https://www.marijuanamoment.net/14-gop-congressional-lawmakers-tell-dea-to-keep-marijuana-in-schedule-i-and-reject-top-health-agencys-recommendation/">urged DEA to "reject" the top federal health agency's recommendation to reschedule marijuana</a>&nbsp;and instead keep it in the most restrictive category under the CSA.
Meanwhile, two GOP senators, including the lead Republican sponsor of&nbsp;<a href="https://www.marijuanamoment.net/watch-live-a-u-s-senate-committee-is-voting-on-a-marijuana-banking-bill/">a marijuana banking bill that cleared a key committee last month</a>, recently filed new legislation to&nbsp;<a href="https://www.marijuanamoment.net/gop-senators-file-bill-to-block-biden-marijuana-rescheduling-effort-without-congressional-approval/">prevent federal agencies from rescheduling cannabis&nbsp;without tacit approval from Congress</a>.

Biotech

CMPS

CYBN

DRUG

ENVB

MNMD

SEEL

'DEA Calls For Massive Increases In Psilocybin, Ibogaine And THC Manufacturing This Year To Meet Research Demands'  - Marijuana Moment

Canadian recreational cannabis retailer Tokyo Smoke entered into a share subscription agreement with TS Investments Corp., its parent company. Under the deal, TS Investments will subscribe to all of the issued and outstanding shares of Tokyo Smoke. 
The deal is valued at roughly $56.7 million (CA$77 million).
What Happened: Tokyo Smoke, <a href="https://www.benzinga.com/markets/cannabis/23/01/30256663/canopy-divests-tweed-and-tokyo-smoke-retail-assets-in-an-effort-to-reach-profitability">previously owned</a> by Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WEED#TSX">WEED</a>), announced in August that it started restructuring its business and obtained an initial order under the Companies Creditors Arrangement Act (CCAA) from the Ontario Superior Court of Justice in Canada. 
As a result, the company agreed to close 29 of its stores, with the continued operation of approximately 167 locations across Ontario, Manitoba, Saskatchewan, Newfoundland and Labrador.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20104058/ccc-oct-24-banner__1_-32.gif" alt="" class="wp-image-558630" /></a></figure>
As part of the stalking horse agreement, the company has received court approval to start a process for selling or restructuring the business. Tokyo Smoke's goal is to explore all options to improve its current situation and is looking for interested buyers or investors who might offer more than what TS Investments is currently offering.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/23/09/34286690/tokyo-smokes-to-feature-travis-organik-fleetwood-weed-brand">Tokyo Smoke To Feature Travis &#8216;Organik&#8217; Fleetwood Weed Brand</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
Why It Matters: Tokyo Smoke seeks to align its operations with current market and regulatory conditions.
The company said it plans to exit from CCAA protection as "a stronger business, better positioned to continue providing premium products to its customers over the long-term while continuing to provide jobs to its dedicated employees across Canada,&#8221; the company said in a press release.
What's Next: The two-phase sale process starts on Friday, Sept.20, including:
<ul>
<li>Phase I, which is intended to solicit non-binding letters of interest. The deadline to submit letters of interest compliant with the sale process terms is Oct. 21, 2024.</li>
<li>Phase II will solicit binding agreements from compliant parties with bids required to be submitted by Nov. 11, 2024.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40591338/canadas-cannabis-growth-slowed-due-to-federal-gov-inaction-key-industry-leader-says">Canada's Cannabis Growth Slowed Due To Federal Gov Inaction, Key Industry Leader Says</a></li>
</ul>
Photo: Courtesy of Pixabay

Retail Sales

Global

TSX:WEED

WEED

Canadian Cannabis Retail Giant Tokyo Smoke Restructures, Seeks Stronger Future Via $56.7M Share Deal

The Czech Republic could be missing out on hundreds of millions of euros annually as the governing coalition remains persistent in avoiding establishing a regulated marijuana market. That's according to the findings of a comprehensive study examining the possible costs and benefits of various cannabis reform models being proposed nationwide.
<h3 class="wp-block-heading">What Happened</h3>
The researchers from the Faculty of Business Economics at the University of Prague concluded that a &#8220;comprehensive model,&#8221; incorporating self-cultivation, cannabis clubs and a fully commercial market, could result in "total net social benefits of CZK 5.5 billion (218 million euros; $242 million) per year," <a href="https://businessofcannabis.com/new-study-backs-full-cannabis-legalisation-in-czech-republic-projecting-czk-5-5bn-in-social-benefits-annually/">reported</a> Business of Cannabis.
The study was published on Thursday, Sept. 12, by the University of Prague. It analyzed each of the cannabis reform models proposed by former National Drug Coordinator Jindřich Vobořil.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16093721/ccc-oct-24-banner__1_-22.gif" alt="" class="wp-image-549705" /></a></figure>
Vobořil left his position this summer, but he continued taking part in the development of addiction policies in the country as an <a href="https://www.benzinga.com/markets/cannabis/24/07/39915786/leaked-document-reveals-czechias-plans-for-cannabis-legalization">independent expert.</a> He previously completed two separate versions of the measure to legalize cannabis.
Vobořil's legislation, which includes commercial sales, seeks to set up a cannabis market <a href="https://www.benzinga.com/markets/cannabis/24/07/39773667/leaked-documents-czech-republic-plans-to-set-up-legal-recreational-cannabis-market">much like that in Canada and certain US states.</a> The other measure mimics Germany's current cannabis framework, with legal home cultivation and cannabis social clubs.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40626067/full-cannabis-legalization-not-yet-off-the-table-in-czech-republic-some-lawmakers-want-only-home">Full Cannabis Legalization Not Yet Off The Table In Czech Republic, Some Lawmakers Want Only Home Grow</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Which Legalization Model Is Most Economically Advantageous?</h3>
That said, the study suggested that legalizing only self-cultivation would yield a net social benefit of CZK 1.2 billion annually and CZK 16.5 billion over the first 11 years. Moreover, putting cannabis clubs into the equation would result in CZK 1.5 billion per year and CZK 20.8 billion over 11 years in social benefits.
However, the highest returns would come from the comprehensive model, featuring a regulated market alongside self-cultivation and clubs, which is projected to deliver CZK 5.5 billion per year and CZK 77.2 billion over 11 years in social benefits.
"The conclusions are very simple,&#8221; Patrik Sieber, one of the study's authors, said. &#8220;All evaluated options appear to be socially and financially more beneficial for public budgets than maintaining the status quo.&#8221;
<h3 class="wp-block-heading">These Cannabis Operators Could Benefit From Policy Change</h3>
In the meantime, cannabis operators have been strengthening their market presence in the European country.
Curaleaf International, part of Curaleaf Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), already present in the European market, opted to expand in the Czech Republic in March, via a new <a href="https://www.benzinga.com/markets/cannabis/24/03/37706111/weed-giants-tilray-and-curaleaf-ramp-up-presence-in-europe-heres-why">supply agreement with Astrasana Pharma s.r.o.</a> Under that deal, Curaleaf International's EU-GMP flower was made available to patients via Pilulka Pharmacy, a healthcare provider in the region.
PharmaCielo Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PCLOF#OTC">PCLOF</a>)'s first shipment of THC-dominant dried cannabis flower to a customer in the Czech Republic <a href="https://www.benzinga.com/markets/cannabis/22/09/28882197/pharmacielo-ships-dried-cannabis-flower-to-the-czech-republic-expanding-its-exports-to-eu">made headlines in 2022.</a>
In 2023, the medical cannabis division of Canadian giant Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) expanded its European footprint across the Czech Republic through a new export and distribution <a href="https://www.benzinga.com/markets/cannabis/23/10/35162207/canopy-growth-shares-up-slightly-in-pre-market-trading-on-eu-gmp-certification-news">partnership with Cansativa Group.</a>
Additionally, Canopy Growth Corporation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WEED#TSX">WEED</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>)&#8217;s medical brands already service European medical markets in Germany, the Czech Republic and Poland as well as Asia-Pacific markets including <a href="https://www.benzinga.com/markets/cannabis/23/10/35162207/canopy-growth-shares-up-slightly-in-pre-market-trading-on-eu-gmp-certification-news">Australia and New Zealand</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39442869/2-9b-european-cannabis-market-a-strategic-blueprint-for-cross-border-transportation-logistics">$2.9B European Cannabis Market: A Strategic Blueprint For Cross-Border Transportation Logistics</a></li>
</ul>

Education

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

PCLOF

This European Country Could Lose $242M A Year If It Doesn't Regulate Its Marijuana Market, Study Finds

SNDL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) announced on Tuesday that Taranvir &#8220;Tank&#8221; Vander, president of its Liquor Division, is stepping down after two decades of leadership in the liquor industry. Vander, who began his career as a liquor store manager in the early 2000s, is retiring to pursue new opportunities.
In 2013, Vander founded Ace Liquor Corporation, expanding it to 15 stores. In 2019, he joined forces with Alcanna Inc., helping it become one of Canada's largest liquor retailers. Zachary George, CEO of SNDL, thanked Vander for his contributions. "We want to thank Tank for his exceptional leadership and wish him continued success in his future endeavors."
Navroop Sandhawalia, VP of finance for Liquor Retail at SNDL, <a href="https://www.prnewswire.com/news-releases/sndl-announces-departure-of-liquor-segment-president-302244048.html#:~:text=CALGARY%2C%20AB%2C%20Sept.%2010,SNDL%20to%20pursue%20new%20opportunities">will take over</a> as interim president of the liquor division while the company searches for a permanent replacement.
Get Benzinga&#8217;s exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">SNDL Stock Performance Compared To Other Canadian Cannabis Companies</h3>
After the market closed on Tuesday, September 10, 2024, SNDL experienced a slight dip in its stock price, closing at $2.10, down 0.47%. Trading volume for SNDL reached 1,697,281 shares, reflecting continued investor activity as the company transitions leadership in its Liquor Division.
In comparison, other notable <a href="https://www.benzinga.com/topic/canada-cannabis">Canadian cannabis stocks</a> also saw mixed results:
<ul>
<li>Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) closed at $5.55, down 1.56%, with 568,615 shares traded. Despite a lower percentage drop than SNDL, Aurora's stock showed greater volatility with a day high of $5.90 and a low of $5.55.</li>
<li>OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) fared slightly better, closing at $1.83, up 1.1%. The stock saw a trading volume of 297,194 shares, indicating moderate investor interest.</li>
<li>Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) closed at $1.69, down 0.59%, with a significant trading volume of 18,592,650 shares, reflecting heightened activity compared to other stocks.</li>
<li>High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) showed positive momentum, increasing by 3.3% to close at $2.13, with 447,671 shares traded, positioning it among the stronger performers in the sector today.</li>
<li>Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) closed at $4.84, down 1.03%, with a volume of 2,777,417 shares. Despite the decline, Canopy saw considerable trading activity, suggesting continued investor engagement.</li>
</ul>
Overall, <a href="https://www.benzinga.com/markets/cannabis/24/08/40631613/sndl-wins-bid-for-indiva-secures-major-deal-to-boost-cannabis-edibles-market-share-in-canada">SNDL's performance </a>was relatively stable compared to its peers, with many Canadian cannabis stocks experiencing minor fluctuations throughout the trading day. The trading volumes across the sector reflected ongoing interest but no significant market shifts following the day&#8217;s developments.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40783919/cannabis-flower-no-thanks-canadians-shift-to-pre-rolls-vapes-as-market-eyes-c-5-47b">Cannabis Flower? No, Thanks: Canadians Shift To Pre-Rolls &amp; Vapes As Market Eyes C$5.47B</a>

Management

 CGC

HITI

Last Call For SNDL's Liquor President: Stock On The Rocks Amid Leadership Changes

Former President Donald Trump announced on Sunday night that, if re-elected, he would reschedule cannabis and support banking reforms for the marijuana industry. He also confirmed his support for Florida's Amendment 3, which would legalize recreational cannabis in the state. Trump's <a href="https://www.benzinga.com/markets/cannabis/24/09/40774795/trump-says-hell-reschedule-cannabis-if-elected-backs-marijuana-banking-reform-and-floridas-amend">comments</a> sparked a reaction in the cannabis stock market on Monday.
Get Benzinga's exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h3 class="wp-block-heading">Stocks Reaction</h3>
<ul>
<li>Trulieve Cannabis (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>): The price at market close was $10.99 with a change of +$1.28 (+13.18%). Trading volume reached 707,392, with a market cap of $2.06 billion.</li>
<li>Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>): The price at market close was $10.66 with a change of +$1.02 (+10.58%). Trading volume hit 473,092, with a market cap of $2.52 billion.</li>
<li>Curaleaf Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>): The price at market close was $3.10 with a change of +$0.26 (+9.15%). Trading volume reached 639,920, and the market cap stood at $2.09 billion.</li>
<li>Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>): The price at market close was $4.86 with a change of +$0.38 (+8.54%). Trading volume was 6,041,892, with a market cap of $412 million.</li>
<li>Sundial Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>): The price at market close was $2.14 with a change of +$0.16 (+8.08%). Trading volume hit 1,946,306, and the market cap was $530 million.</li>
<li>Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>): The price at market close was $5.80 with a change of +$0.39 (+7.25%). Trading volume was 1,136,294, with a market cap of $317 million.</li>
<li>Cronos Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>): The price at market close was $2.21 with a change of +$0.07 (+3.27%). Trading volume reached 1,448,055, with a market cap of $847 million.</li>
<li>HEXO Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEXO#NASDAQ">HEXO</a>): The price at market close was $1.35 with a change of +$0.05 (+3.85%). Trading volume was 1,215,840, with a market cap of $401 million.</li>
<li>AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>): The price at market close was $7.16 with a change of +$0.75 (+11.70%). Trading volume hit 13,998,304.</li>
<li>Innovative Industrial Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>): The price at market close was $122.69 with a change of +$2.02 (+1.67%). Trading volume was 90,181, with a market cap of $3.42 billion.</li>
<li>GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>): The price at market close was $1.92 with a change of +$0.05 (+2.96%). Trading volume hit 454,306, and the market cap was $110 million.</li>
<li>Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>): The price at market close was $52.48 with a change of +$2.43 (+4.87%). Trading volume was 153,424, with a market cap of $630 million.</li>
<li>AdvisorShares Pure Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOLO#NYSE">YOLO</a>): The price at market close was $3.35 with a change of +$0.21 (+6.69%). Trading volume reached 37,519.</li>
<li>Scotts Miracle-Gro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>): The price at market close was $67.62 with a change of -$0.20 (-0.29%). Trading volume reached 323,540, with a market cap of $3.85 billion.</li>
<li>Village Farms International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>): The price at market close was $1.01 with a change of +$0.01 (+1.02%). Trading volume hit 459,136, and the market cap was $113 million.</li>
<li>Trees (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CANN#OTC">CANN</a>): The price at market close was $0.042 with a change of -$0.012 (-22.22%). Trading volume was 118,407.</li>
<li>Medical Marijuana (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MJNA#OTC">MJNA</a>): The price at market close was $0.001 with no change. Trading volume hit 9,393,761, with a market cap of $5.68 million.</li>
<li>OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>): The price at market close was $1.83 with a change of +$0.08 (+4.29%). Trading volume was 348,054, with a market cap of $186 million.</li>
<li>High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>): The price at market close was $2.12 with a change of +$0.16 (+8.16%). Trading volume hit 648,008, with a market cap of $162 million.</li>
<li>Planet 13 Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PLNHF#OTC">PLNHF</a>): The price at market close was $0.96 with no significant change. Trading volume was 275,004.</li>
<li>Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>): The price at market close was $1.74 with a change of +$0.13 (+7.74%). Trading volume hit 438,517, with a market cap of $565 million.</li>
</ul>
<h3 class="wp-block-heading">Highs And Lows In 2024&nbsp;</h3>
The cannabis market has experienced several significant stock movements in recent months. On April 30, 2024, stocks soared after the DEA announced plans to reschedule cannabis to Schedule III, with Canopy Growth <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38536953/cannabis-stocks-react-to-dea-rescheduling-canopy-aurora-surge-tilray-wm-tech-hold-s">jumping</a> by 78.8% and Aurora Cannabis rising 46%. 
However, two weeks ago, following the DEA's decision to delay its final ruling, the sector saw a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40580306/cannabis-stocks-plummet-by-up-to-16-on-dea-rescheduling-delay-could-this-be-the-buy">sharp decline</a>, with Curaleaf falling 15.68% and Green Thumb Industries dropping 10.15%. In contrast, Monday's gains following Trump's support for Amendment 3 were more modest, with a mean growth of 4.31%, suggesting a recovery but not on the same scale as the April surge.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40776937/trump-joins-millions-of-americans-who-support-rescheduling-cannabis-weed-industry-responds-to-fo">Trump &#8216;Joins Millions Of Americans&#8217; Who Support Rescheduling Cannabis: Weed Industry Responds To Former Pres&#8217; News</a>

CANN

CRLBF

GTBIF

HEXO

IIPR

MJNA

PLNHF

TCNNF

YOLO

Cannabis Stocks React To Trump's Marijuana Comments: See Which Ones Posted Solid Gains

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 40.59% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 40.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 16.67% at $0.33</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 12.00% at $0.25</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 11.11% at $0.18</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 11.06% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 10.53% at $2.09</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed up 10.31% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 10.31% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 10.04% at $4.85</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 9.86% at $3.11</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 8.36% at $1.75</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 7.66% at $0.18</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed up 7.39% at $5.76</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed up 6.06% at $2.12</li>
<li><a href="https://www.benzinga.com/quote/OGI">OrganiGram Holdings</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed up 5.71% at $1.82</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 5.45% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 5.34% at $52.71</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 4.94% at $1.70</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 4.30% at $1.93</li>
<li><a href="https://www.benzinga.com/quote/CRON">Cronos Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) shares closed up 3.74% at $2.21</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 3.64% at $5.19</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 3.22% at $10.81</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CWWBF">Plant Based Investment</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWWBF#OTC">CWWBF</a>) shares closed down 99.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/ACNNF">AusCann Group Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ACNNF#OTC">ACNNF</a>) shares closed down 66.67% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 28.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 26.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 19.78% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 18.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed down 17.63% at $1.13</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 12.42% at $2.79</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 10.79% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 9.06% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 6.20% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 5.42% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 5.41% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed down 5.06% at $11.07</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACNNF

MRMD

Marijuana Stock Movers For September 9, 2024

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 45.45% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed up 42.63% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 10.02% at $0.27</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 5.26% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed up 3.53% at $0.57</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 3.23% at $0.03</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/AUSAF">Australis Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUSAF#OTC">AUSAF</a>) shares closed down 99.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 33.33% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed down 31.05% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 22.73% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 16.23% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 16.13% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 11.47% at $3.22</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 9.09% at $0.23</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 8.12% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed down 6.86% at $0.12</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 6.48% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 5.95% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 5.68% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 5.60% at $2.84</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 5.53% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 5.06% at $4.48</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 4.05% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed down 3.44% at $0.33</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed down 3.21% at $5.41</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLOZF

MGWFF

RSSFF

Cannabis Stock Movers For September 6, 2024

The cannabis market is abuzz following former President Donald Trump&#8217;s recent comments supporting cannabis legalization in Florida.&nbsp;
During a podcast interview, Trump <a href="https://www.benzinga.com/markets/cannabis/24/09/40697992/trump-talks-legal-weed-on-lex-fridman-podcast-we-can-live-with-the-marijuana">backed the state&#8217;s recreational cannabis initiative </a>and emphasized the need for a lawful and regulated framework.&nbsp;
This comes as Florida prepares to vote on a ballot initiative in November, which could reshape the cannabis landscape.
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Top Performers And Decliners After Trump&#8217;s Comments On Marijuana </h3>
Stocks in the cannabis sector showed varied reactions on Wednesday, after <a href="https://www.benzinga.com/markets/cannabis/24/09/40677600/harris-campaign-slams-donald-trump-over-cannabis-shift-calls-it-brazen-flip-flop">Trump&#8217;s comments</a>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOLO#NYSE">YOLO</a>) AdvisorShares Pure Cannabis ETF led the gainers, climbing 3.48% to $3.27, reflecting investor optimism around potential federal changes.&nbsp;
(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CANN#OTC">CANN</a>) Trees Corporation experienced a plunge, down 99.8%, closing at $0.0001. Among the notable losers, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) Canopy Growth dropped 3.37% to $4.87, and (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) Cronos Group slipped 1.79% to $2.20.
Other stocks remained relatively stable. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) Tilray Brands fell 1.19%, ending at $1.67, and (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) Aurora Cannabis dipped 1.37% to $5.76.&nbsp;
Meanwhile, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) Sundial Growers climbed 2.53%, closing at $2.00, and (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) Trulieve Cannabis posted a 3.72% gain to $9.75, reflecting positive sentiment around these companies.
Read Also:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/09/40712816/what-trump-learned-about-marijuana-that-desantis-did-not-and-why-the-gop-might-become-weed-frien">What Trump Learned About Marijuana That DeSantis Did Not And Why The GOP Might Become Weed-Friendly</a>
<h3 class="wp-block-heading">Stocks To Watch </h3>
<ul>
<li>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) AdvisorShares Pure US Cannabis ETF ended the day with a slight decline of 0.31%, closing at $6.48.</li>
<li>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) Innovative Industrial Properties, a key player in cannabis real estate, dropped 0.82%, closing at $121.58, showing a more cautious response from investors.&nbsp;</li>
<li>(OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) Green Thumb Industries posted a modest gain of 0.67%, closing at $9.83, indicating optimism.&nbsp;</li>
<li>(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MJNA#OTC">MJNA</a>) Medical Marijuana Inc. surged 10%, finishing at $0.0011, reflecting renewed interest despite its low price point.</li>
</ul>
Read Next:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/09/40713542/2024-election-cannabis-swing-state-voters-back-legalization-new-poll-reveals">2024 Election &amp; Cannabis: Swing State Voters Back Legalization, New Poll Reveals</a>

Small Cap Analysis

Trump's Marijuana Support Could Ignite Stock Surge – Are You Positioned To Benefit?

Canopy Growth's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) international subsidiary Canopy Growth Polska is withdrawing its medical marijuana strain Penelope from the market, <a href="https://born2invest.com/articles/canopy-growth-withdraws-penelope-cannabis/">writes</a> Born2Invest. One of the leading suppliers of medical marijuana in Poland decided to withdraw the popular strain that contains 8% THC and 7% CBD due to the aging of the strain, which has made its quality unstable.
"The decision to discontinue Penelope was very difficult for us, as it is a strain that enjoyed huge interest. However, our commitment to providing only the highest quality products forced us to take this step," said a representative of Canopy Growth Polska.
The Penelope strain was one of the company's flagship products, mostly because of its balanced content of the cannabinoids. However, over time, the genetics of the plant can weaken, causing instability of the product.
Canopy Growth Polska is working on the introduction of other new strains that have a similar profile to Penelope. These products are expected to reach the market in the near future.
"The process of registering new varieties of medical cannabis in Poland is time-consuming, but we are constantly working to provide patients with appropriate substitutes as quickly as possible. Our goal is to ensure continuity of therapy and support for doctors and patients," said the company representative.
Continue <a href="https://born2invest.com/articles/canopy-growth-withdraws-penelope-cannabis/">reading</a> on Born2Invest.
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Medical Market Booming</h2>
In August, the government of Poland announced it <a href="https://www.benzinga.com/markets/cannabis/24/08/40441445/3-years-after-cannabis-reform-in-malta-regulator-says-harm-reduction-approach-is-working-more-po" target="_blank" rel="noreferrer noopener">intends to tighten medical marijuana rules</a> to address concerns of possible misuse. In 2019, only 2,909 cannabis prescriptions were issued, but this number skyrocketed to 276,807 in 2023, marking a <a href="https://www.benzinga.com/markets/cannabis/24/06/39435550/polands-medicinal-cannabis-boom-prescriptions-up-9-420-dispensation-up-13-942-in-just-4-years" target="_blank" rel="noreferrer noopener">9,420% increase</a> over that period.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/04/38146863/154-pounds-of-weed-found-in-french-mayors-home-denmark-closes-pot-street-in-christiania-after-mu" target="_blank" rel="noreferrer noopener">Poland's Medicinal Cannabis Boom: Prescriptions Up 9,420%, Dispensation Up 13,942% In Just 4 Years</a>
The potential of Poland&#8217;s medical marijuana market was recognized this year by U.S. cannabis giant Curaleaf Holdings (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTCQX">CURLF</a>), whose subsidiary Curaleaf International expanded in Poland via the <a href="https://www.benzinga.com/markets/cannabis/24/02/36958982/cannabis-giant-curaleaf-expands-in-this-european-country-via-new-acquisition" target="_blank" rel="noreferrer noopener">acquisition of Can4Med</a>, the country's pharmaceutical wholesaler specializing in cannabinoid medication.
In line with the increasing medical marijuana use, the Polish Public Opinion Research Center (CBOS) recently revealed that 73.4% of Poles support the decriminalization of cannabis. However, recreational cannabis use remains illegal.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40643378/sri-lankas-cannabis-investment-plan-attracts-30-applications-philippines-rep-pushes-for-medical-">Poland: Drivers Entering From Germany Should Be Aware Of Cannabis Zero-Tolerance Policy</a></li>
</ul>
Photo generated with AI

Eurozone

Canopy Growth Withdraws Medical Marijuana Strain Penelope In Poland, Citing Aging Genetics, Quality Concerns

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 31.33% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 27.33% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 13.30% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed up 7.00% at $0.13</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 3.75% at $0.25</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 3.37% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed up 3.25% at $13.66</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 33.82% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/ACNNF">AusCann Group Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ACNNF#OTC">ACNNF</a>) shares closed down 27.42% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 16.85% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 16.67% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 13.10% at $3.78</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 11.11% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 6.25% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 6.06% at $0.54</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 5.20% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 4.17% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 4.14% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 3.82% at $0.28</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 3.47% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed down 3.23% at $1.87</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 3.18% at $4.87</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Marijuana Stock Movers For September 4, 2024

If you are wary of the volatility of cannabis stocks then consider the 5 tobacco, beer, and distiller/vintner companies that have major investments in the cannabis sector. Their stock returns outperformed both our MSO and LP cannabis portfolios.

Our Conservative "Cannabis" Portfolio Performed Better In August (and YTD) Than Either OUR MSO Or LP Portfolios

If you are wary of the volatility of cannabis stocks then consider the 5 tobacco, beer, and distiller/vintner companies that have major investments in the cannabis sector.

Our Conservative "Cannabis" Portfolio Performed Better In August (And YTD) Than Either Our MSO Or LP Portfolios

Look For Tilray To Keep Declining

The past present and future of the Canadian cannabis sector.

The Canadian Cannabis Report - Monday, Sept. 9

Our LP portfolio was down 10% last week as a result of the August 26th announcement by the DEA that it had scheduled an administrative hearing for December 2nd to consider differing expert opinions on the proposal that cannabis be re-classified.

Canadian Cannabis LP Stocks Portfolio -10% W/e Sept. 6th

Canopy Growth (TSE:WEED) has released an update. Canopy Growth Corporation is calling on its shareholders to vote in the upcoming annual general me...

Canopy Growth Seeks Crucial Shareholder Votes

The Canadian Cannabis LP Stocks Portfolio was up +6% last week from a 10% decline w/e Sept. 6th as the negative sentiment waned surrounding the DEA's announcement that it would be having a December 2nd hearing to consider additional opinions

Cannabis LP Stocks Were +6% Last Week Vs. -10% The Previous Week

Our Conservative Cannabis Stocks Portfolio has outperformed our Canadian Cannabis LP Stocks Portfolio by more than a 3 to 1 margin on an annual basis. As such, our conservative cannabis portfolio is just that - a conservative cannabis investment.

Our Conservative Cannabis Stock Portfolio Continues To Outperform

Canopy Growth (TSE:WEED) has released an update. Canopy Growth Corporation has extended the proxy voting deadline for its annual general meeting to...

Canopy Growth Extends Voting Deadline to Secure Quorum

Canopy Growth (TSE:WEED) has released an update. Canopy Growth Corporation reports a successful annual general meeting with all proposed resolution...

Comments

Canopy Gwth

Actualités

Dernières nouvelles pour Canopy Gwth (NASDAQ:CGC) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL